ATC Group: N02CC Selective serotonin (5HT1) agonists

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N02CC in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N02 Analgesics
3 N02C Antimigraine preparations
4 N02CC Selective serotonin (5HT1) agonists

Group N02CC contents

Code Title
N02CC01 Sumatriptan
N02CC02 Naratriptan
N02CC03 Zolmitriptan
N02CC04 Rizatriptan
N02CC05 Almotriptan
N02CC06 Eletriptan
N02CC07 Frovatriptan
N02CC08
N02CC51

Active ingredients in N02CC

Active Ingredient

Almotriptan is a selective 5-HT1B and 5-HT1D receptor agonist. These receptors mediate vasoconstriction of certain cranial vessels, as demonstrated in studies using isolated human tissue preparations.

Eletriptan is a selective agonist at the vascular 5-HT1B and neuronal 5-HT1D receptors. Eletriptan also exhibits high affinity for the 5-HT1F receptor which may contribute to its anti-migraine mechanism of action.

Frovatriptan is a selective agonist for 5-HT receptors. Frovatriptan is believed to act selectively on extracerebral, intracranial arteries to inhibit the excessive dilatation of these vessels in migraine.

Naratriptan has been shown to be a selective agonist for 5 hydroxytryptamine1 (5-HT1) receptors mediating vascular contraction. This receptor is found predominantly in intracranial (cerebral and dural) blood vessels. Naratriptan is indicated for the acute treatment of migraine attacks with or without aura.

Rizatriptan binds selectively with high affinity to human 5-HT1B and 5-HT1D receptors. The therapeutic activity of rizatriptan in treating migraine headache may be attributed to its agonist effects at 5-HT1B and 5-HT1D receptors on the extracerebral intracranial blood vessels that are thought to become dilated during an attack and on the trigeminal sensory nerves that innervate them.

Sumatriptan has been demonstrated to be a specific and selective 5-Hydroxytryptamine1 (5HT1D) receptor agonist with no effect on other 5HT receptor (5-HT2 - 5-HT7) subtypes. The vascular 5-HT1D receptor is found predominantly in cranial blood vessels and mediates vasoconstriction.

Zolmitriptan has been demonstrated to be a selective agonist for the vascular human recombinant 5HT1B and 5HT1D receptor subtypes. Zolmitriptan is a high affinity 5HT1B/1D receptor agonist with modest affinity for 5HT1A receptors.

Related product monographs

Document Type Information Source  
 ALMOGRAN Film-coated tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 AMERGE Film-coated tablet MPI, US: SPL/PLR FDA, National Drug Code (US)
 FROVA Tablet MPI, US: SPL/PLR FDA, National Drug Code (US)
 IMIGRAN Nasal spray, solution MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 IMIGRAN Solution for injection MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 IMIGRAN Tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 IMITREX Film-coated tablet MPI, US: SPL/PLR FDA, National Drug Code (US)
 IMITREX Nasal spray MPI, US: SPL/PLR FDA, National Drug Code (US)
 IMITREX Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 MAXALT Tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 MIGARD Film-coated tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 NARAMIG Tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 RELPAX Film-coated tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 REYVOW Tablet MPI, US: SPL/PLR FDA, National Drug Code (US)
 SUMATRAN Tablet MPI, EU: SmPC Health Products Regulatory Authority (IE)
 ZOMIG Film-coated tablet MPI, EU: SmPC Υπουργείο Υγείας (CY)
 ZOMIG Nasal spray MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)